MeiraGTx Holdings plc (MGTX)
MGTX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1735438/000110465926036494/0001104659-26-036494-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MGTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001735438 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $81.4M |
| Net income | -$114.2M |
| Operating income | -$106.0M |
| Net margin | -140.3% |
| Operating margin | -130.2% |
| Revenue growth | +144.6% |
| Cash | $65.9M |
| Total assets | $244.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 10.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $184.7M cash; operating cash flow $339K a quarter. | Report 2026-09-30 |
| Shares outstanding | 97,730,540 (2026-11-04); 80,490,889 a year earlier; 63,597,151 three years earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-04-16 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Jericho, New York, United States | PCAOB Form AP 2026-04-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $4.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $4.8M | -$51.2M | -$24.5M | $184.7M | No debt tags | $401.9M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $321.4M | $160.7M | -$38.5M | $143.2M | No debt tags | $397.5M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $293K | -$46.3M | $17.8M | $71.5M | $24.9M | $79.8M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $75.4M | $15.1M | $46.6M | $65.9M | $24.6M | $81.4M | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | $410K | -$50.5M | -$12.2M | $14.8M | $74.1M | $27.4M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $3.7M | -$38.8M | -$43.9M | $32.2M | No debt tags | $37.9M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $1.9M | -$40.0M | -$36.8M | $66.5M | No debt tags | $34.5M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $21.4M | -$39.4M | -$23.3M | $103.7M | No debt tags | $33.3M | 10-K 2026-03-30 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-11-12 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 513 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.0% |
| 1 month | -7.6% |
| 3 months | -27.5% |
| Year to date | +15.5% |
| 1 year | +11.1% |
| From 52-week high | -38.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMTX | Immatics N.V. | $6.17 | -3.44% | $923.2M |
| ODTX | Odyssey Therapeutics Inc. | $19.36 | +1.15% | $930.6M |
| GLUE | Monte Rosa Therapeutics Inc. | $9.16 | -2.24% | $782.7M |
| PRME | Prime Medicine Inc. | $4.19 | -1.87% | $762.3M |
| AURA | Aura Biosciences Inc. | $7.22 | +1.55% | $751.4M |
| SLDB | Solid Biosciences Inc. | $6.48 | -5.26% | $723.2M |
| ATTO | Attovia Therapeutics Inc. | $14.72 | -2.68% | $673.1M |
| DBVT | DBV Technologies S.A. | $10.27 | -6.76% | $645.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier